Keywords
Depressive Disorder, Major ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

210 Search results.

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Major Depression Episode (MDE) Follow-up (Major Depression Episode (MDE) Follow-up)

- 4/9/20 - 1 form, 3 itemgroups, 23 items, 1 language
Itemgroups: Administrative Data, Major Depression Episode (MDE), Major Depression Episode (MDE) since last visit
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Major Depression Episode (MDE) Follow-up form. It has to be filled in for follow-up visits. For use of this questionnaire no licence is required.

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Major Depression Episode (MDE) Baseline (Major Depression Episode (MDE) Baseline)

- 4/9/20 - 1 form, 4 itemgroups, 26 items, 1 language
Itemgroups: Administrative Data, Major Depression Episode (MDE), Major Depression Episode (MDE) lifetime, MDE - Lifetime
DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the Major Depression Episode (MDE) Baseline form. It has to be filled in for Baseline. For use of this questionnaire no licence is required.

Eligibility Unipolar Major Depressive Disorder NCT01875419

- 12/31/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Non-invasive Brain Stimulation and Cognitive Processing in Depression; ODM derived from: https://clinicaltrials.gov/show/NCT01875419

Eligibility Major Depressive Disorder NCT02476058

- 5/7/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder; ODM derived from: https://clinicaltrials.gov/show/NCT02476058

Eligibility Major Depressive Disorder NCT02454426

- 5/7/19 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Inclusion Criteria
Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02454426

Eligibility Major Depressive Disorder NCT02507219

- 5/7/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Ibuprofen Effects on Brain Function; ODM derived from: https://clinicaltrials.gov/show/NCT02507219

Eligibility Major Depressive Disorder NCT02460666

- 5/6/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Brain Connectivity and Response to Tai Chi in Geriatric Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02460666

Eligibility Major Depressive Disorder NCT02440815

- 5/6/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02440815

Eligibility Major Depressive Disorder NCT02429011

- 5/6/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MRI Studies of Emotion in Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02429011

Eligibility Major Depressive Disorder NCT02395978

- 5/6/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder; ODM derived from: https://clinicaltrials.gov/show/NCT02395978

Eligibility Major Depressive Disorder NCT02330744

- 5/5/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The Neurobiology of Approach Avoidance Training in Depression; ODM derived from: https://clinicaltrials.gov/show/NCT02330744

Eligibility Major Depressive Disorder NCT02330068

- 5/5/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Microbiome of Depression & Treatment Response to Citalopram; ODM derived from: https://clinicaltrials.gov/show/NCT02330068